Anti-inflammatory Therapy for Recurrent In-stent Restenosis
Status:
Not yet recruiting
Trial end date:
2026-10-29
Target enrollment:
Participant gender:
Summary
This study is aimed at making a comparison of the safety and efficacy of standard drug
therapy (control group), standard drugs combined with lose-dose colchicine therapy
(colchicine group) and standard drug combined with prednisone therapy (prednisone group) in
patients with coronary heart disease who suffered from recurrent In-stent restenosis (RISR).